Notifications
Clear all
Topic starter
17/10/2019 6:37 pm
"When compared with patients who received the regimen only at full doses, the patients given reduced doses had better overall survival. Patients who underwent at least one dose reduction had a median survival time of 9.27 months (95% CI, 7.23-11.30), versus 4.37 months (95% CI, 1.13-7.60) in patients who did not undergo dose reductions. “We assume this was due to less toxicity with dose reductions”